IV (AbD Serotec), XRCC4 (#ab2857, Abcam), XLF (#2854, CST), MRE11 (#4895, CST), RAD50 (MAI-23269, Thermo-Scientific), RAD51 (#ab213, Abcam), NBS1 (#3002, CST), BRCA1 (#ab16780, Abcam), RPA32 (#ab10359, Abcam), phospho-S824 KAP-1 (#A300-274A, Bethyl Lab. Inc), KAP-1 (#A300-767A, Bethyl Lab. Inc), phospho-T68 Chk-2 (#2661, CST), Chk-2 (#2662, CST), phospho-S15 p53 (#9284, CST), β-tubulin (#T4026, Sigma) and myosin Iib (#3404, CST). Supplementary Table S1 Control AZ12253801 Time ( There were no significant differences by t-test between mean values for control and 30nM AZ12253801-treated cells. Lower: cells were treated with solvent or 30nM AZ12253801 for 4hr, irradiated (3Gy) and harvested at intervals for cell cycle analysis. No significant differences were found between control and AZ12253801treated cells.
Supplementary Tables

Supplementary Table S2
AZ12253801 nM G1 (%) S (%) G2/M (%) 0 57.6 ± 0.5 16.8 ± 0.5 25.6 ± 0.5 30 47.4 ± 0.6 20.6 ± 1.3 31.9 ± 0.9 60 45.0 ± 0.7 20.2 ± 0.4 34.8 ± 0.3
Legend to Supplementary Table S2 . Effects of AZ12253801 on cell cycle distribution of NHEJ reporter HEK293 cells. Triplicate samples of solvent (control) or AZ12253801-treated EJ5-GFP-TST HEK293 cells were subject to cell cycle analysis as Supplementary Figure S6 . Table: mean ± SEM % cells in each cell cycle phase.
Legends to Supplementary Figures
Figure S1 AZ12253801 SF 50 interpolation in R+ cells. R+ cell survival data from Figure 1c plotted with linear y-axis to show SF 50 interpolation.
Figure S2 Effect of IGF-1R inhibition on radiosensitivity of PC3, 22Rv1 and
LNCaP-LN3 cells. Cells were treated with solvent, AZ12253801 at or below the SF 50 for each cell line, or 3µM ATM inhibitor KU55933. After 11-12 days, visible colonies were stained and counted, and cell survival was expressed as % survival in solvent-treated controls. Points represent the mean ± SEM for triplicate values from three independent experiments in each cell line. In PC3 cells, AZ12253801 at 30nM enhanced sensitivity to 3 Gy (*p<0.05) and at 60nM to 1 Gy (p<0.05), 3 Gy (p<0.01) and 5 Gy (p<0.05 by one way ANOVA). KU55933 also radiosensitized PC3 cells (p<0.001 at 3 Gy, p<0.05 at 5 Gy compared with control-treated cells) but did not show statistically significant radiosensitization compared with 30 or 60 nM AZ12253801. In 22Rv1 cells, 30nM AZ12253801 enhanced sensitivity to 1 and 3 Gy (p<0.01), effects that were not significantly different from radiosensitization induced by ATM inhibition. AZ12253801-pre-treated LNCaP-LN3 cells showed minor enhancement of sensitivity to 1 Gy (52 ± 3% survival compared with 64 ± 2% in controls, p<0.05), but there were no differences at 3-5 Gy and no change in radiosensitivity in cells treated with KU55933. upper, solvent (control) or 30nM AZ12253801 for 4hr then collected at intervals of 1-24hr; lower: treated for 4hr with solvent or AZ12253801 as above, irradiated (3 Gy), and collected at intervals post-irradiation. FlowJo 7.6.5 software was used to assign G1, S and G2/M phases, and the data are summarized in Supplementary Table S1 . (Table 1) . After 4hr, cells were irradiated (3Gy), and at intervals fixed and stained for S139 γH2AX to quantify γH2AX foci as Legend to Figure 4c cell cycle profiles were determined as in Figure S3 , and the data are summarized in Supplementary Table S2 . 
